论文部分内容阅读
采用双抗体夹心酶联免疫吸附试验检测３２例手术前后和２６例化疗前后肺癌患者的血清可溶性白细胞介素－２受体（ｓＩＬ－２Ｒ）水平并与２９例健康人进行比较。结果显示：肺癌患者血清ｓＩＬ－２Ｒ水平明显高于正常对照组（Ｐ＜０．０１）。术后患者血清ｓＩＬ－２Ｒ水平明显下降（Ｐ＜０．０１）；术前血清ｓＩＬ－２Ｒ水平与肿瘤组织分化密切相关，分化越低，水平越高（Ｐ＜０．０５），但与肿瘤病理类型和分期无明显的关系（Ｐ＞０．０５）。化疗前后ｓＩＬ－２Ｒ水平变化不明显（Ｐ＞０．０５）。，而且ｓＩＬ－２Ｒ水平下降与化疗疗效也无明显的关系（Ｐ＞０．０５）。结果表明肺癌患者血清ｓＩＬ－２Ｒ水平与肿瘤负荷和肿瘤分化密切相关，血清ｓＩＬ－２Ｒ水平动态监测可以作为判断手术效果和肿瘤预后的重要指标。
The levels of soluble interleukin-2 receptor (sIL-2R) in 32 patients with lung cancer before and after surgery and 26 patients before and after chemotherapy were measured by double-antibody sandwich enzyme-linked immunosorbent assay and compared with 29 healthy individuals. The results showed that serum sIL-2R levels in lung cancer patients were significantly higher than those in normal controls (P<0.01). Serum sIL-2R levels were significantly decreased after surgery (P<0.01). Preoperative serum sIL-2R levels were closely related to tumor tissue differentiation. The lower the differentiation, the higher the level (P<0.05). There was no significant relationship between pathological type and stage (P>0.05). There was no significant change in sIL-2R levels before and after chemotherapy (P>0.05). And there was no significant relationship between the decrease of sIL-2R level and chemotherapy efficacy (P>0.05). The results showed that serum sIL-2R levels in lung cancer patients are closely related to tumor burden and tumor differentiation. Dynamic monitoring of serum sIL-2R levels can be used as an important indicator to judge the surgical outcome and tumor prognosis.